The concept of “socially-responsible licensing”, which seeks either to ensure socially-beneficial use of technologies or to avoid socially-negative use of licensed IP, , has developed over the last 10-15 years.
A large number of university-level institutions seek to include some licence terms that relate to these objectives, and may large multinationals in the pharmaceutical field, have adopted public pledges (e.g. AstraZeneca’s commitment that it will not profit from the Oxford-AstraZeneca COVID-19 vaccine during the pandemic) or developed other initiatives (e.g. GSK’s creation of royalty-free licensing arrangements, in connection with IP related to neglected tropical diseases.)
Global interest in this area has been heightened following contemporary news coverage of “IP waivers”, and discussion of concerns that relate both to maintaining effective incentives to innovation and global access to medicines.
These high-level events, which arise from the unprecedented nature of the pandemic, are likely to have significant effects on the views of institutions and to affect everyday technology licensing practices and approaches.
This webinar will reflect on how licensing practitioners and IP academics see the current landscape, consider how industry can respond to address the concerns of civil society stakeholders, and suggest how licensing practices may change in the future.
This event is free to participants.